University of Utah, Huntsman Cancer Institute
Welcome,         Profile    Billing    Logout  
 44 Trials 
66 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Agarwal, Neeraj
S1216, NCT01809691: , Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Active, not recruiting
3
1313
US
TAK-700, Orteronel, Bicalutamide, Casodex
SWOG Cancer Research Network, Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI)
Prostate Cancer
03/22
10/27
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
PemCab, NCT03534804: Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

Completed
2
37
US
Cabozantinib, XL184, Pembrolizumab
University of Utah, Exelixis
Metastatic Urothelial Carcinoma, Bladder Cancer
08/23
04/24
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
Shami, Paul J
NCT05532722: ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Active, not recruiting
1/2
21
US
ABC008
Abcuro, Inc.
T-cell Large Granular Lymphocytic Leukemia
09/25
09/27
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 
Colman, Howard
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT03994796: Genetic Testing in Guiding Treatment for Patients with Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/26
06/28
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
PNOC025, NCT05169944: Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

Completed
1
13
US
Magrolimab, Anti-CD47 Monoclonal Antibody
University of California, San Francisco, Gilead Sciences
Brain Cancer, Malignant Brain Tumor, Recurrent Brain Tumor, Progressive Malignant Brain Tumor, Brain Tumor, Pediatric, Brain Tumor Adult
09/24
09/24
NCT05739942: Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Recruiting
1
48
Europe, US, RoW
[177Lu]Lu-NeoB, Lu-NeoB, [68Ga]Ga-NeoB, Ga-NeoB, Temozolomide
Novartis Pharmaceuticals
Newly Diagnosed and Recurrent Glioblastoma
02/26
08/31
Paulson, Scott
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
daNIS-2, NCT04935359 / 2021-000591-10: Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) -

Completed
3
511
Europe, Canada, Japan, US, RoW
NIS793, Nab-paclitaxel, Gemcitabine, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Pancreatic Ductal Adenocarcinoma
08/24
08/24
TAS-102 NEC, NCT04042714: TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

Recruiting
2
14
US
All patients- TAS-102, Trifluridine, Tipiracil
Baylor Research Institute, Taiho Oncology, Inc.
High-grade Extra Pulmonary Neuroendocrine Cancer
08/23
08/23
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT05630183: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Hourglass Jan 2024 - Jun 2024 : Results from C-800-22 trial for 2L metastatic pancreatic cancer
Recruiting
2
78
US
Botensilimab, AGEN1181, Gemcitabine, Nab-paclitaxel
Agenus Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
12/24
12/24
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NET-202, NCT05997056: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Recruiting
2
21
US
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
05/25
12/25
DUET-1, NCT05120271 / 2021-005086-41: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Recruiting
1/2
110
Europe, US
CAR-GPC3 T Cells, BOXR1030
Sotio Biotech Inc., SOTIO Biotech AG, SOTIO Biotech a.s.
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
10/27
12/42
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
NCT06415487: ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Recruiting
1
30
US, RoW
Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab
Acepodia Biotech, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
12/26
03/27
Soares, Heloisa
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
daNIS-2, NCT04935359 / 2021-000591-10: Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) -

Completed
3
511
Europe, Canada, Japan, US, RoW
NIS793, Nab-paclitaxel, Gemcitabine, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Pancreatic Ductal Adenocarcinoma
08/24
08/24
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
daNIS-3, NCT04952753 / 2021-000553-40: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Completed
2
204
Europe, Canada, Japan, US, RoW
NIS793, Bevacizumab, Modified FOLFOX6, 5FU+Leucovorin+Oxaliplatin, FOLFIRI, 5FU+Leucovorin+Irinotecan, Tislelizumab, VDT482
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Colorectal Cancer
01/25
01/25
NCT05420636: Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Hourglass Sep 2022 - Dec 2022 : First-patient-in of trial for r/r SCLC and extrapulmonary high grade neuroendocrine tumors
Recruiting
2
42
US
Iadademstat, Paclitaxel
Fox Chase Cancer Center, Oryzon Genomics S.A.
Small-cell Lung Cancer, Neuroendocrine Carcinoma
08/25
08/26
Hu-Lieskovan, Siwen
BA3071-001, NCT05180799: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Recruiting
1/2
320
US, RoW
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
BioAtla, Inc.
NSCLC, Melanoma
12/25
06/26
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
159
US, RoW
AU-007, Aldesleukin, Avelumab
Aulos Bioscience, Inc.
Advanced Solid Tumor, Metastatic Cancer
08/25
09/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
KEYNOTE-C82, NCT04648202: FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Active, not recruiting
1
82
Europe, US
FS120, Pembrolizumab (KEYTRUDA®)
invoX Pharma Limited, Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
03/26
03/26
CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting
1
438
Europe, US, RoW
DF6002, Nivolumab, Opdivo
Dragonfly Therapeutics
Solid Tumors
01/27
11/27
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
Vijayvergia, Namrata
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
NCT05420636: Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Hourglass Sep 2022 - Dec 2022 : First-patient-in of trial for r/r SCLC and extrapulmonary high grade neuroendocrine tumors
Recruiting
2
42
US
Iadademstat, Paclitaxel
Fox Chase Cancer Center, Oryzon Genomics S.A.
Small-cell Lung Cancer, Neuroendocrine Carcinoma
08/25
08/26
NCT05274048: Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Recruiting
1
18
US
Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Fox Chase Cancer Center, National Comprehensive Cancer Network, Puma Biotechnology, Inc.
Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
06/25
06/27
Maese, Luke
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
LEOPARD, NCT06068075: Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic:

Recruiting
N/A
340
US
FoundationOne Liquid CDx, Liquid Biopsy
Dana-Farber Cancer Institute, Alex's Lemonade Stand Foundation, Conquer Cancer Foundation, Harvard University, Sam Day Foundation
Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
01/25
01/26
Kingsford, Rachel
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
39
Japan, US
DSP-0390
Sumitomo Pharma America, Inc.
High Grade Glioma, Glioblastoma Multiforme
09/26
10/26
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
Broghammer, Jill
PemCab, NCT03534804: Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

Completed
2
37
US
Cabozantinib, XL184, Pembrolizumab
University of Utah, Exelixis
Metastatic Urothelial Carcinoma, Bladder Cancer
08/23
04/24
Johnson, Brett
NCT06422312: A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.

Not yet recruiting
N/A
140
US
Cystoscopy with RedPine flexible disposable cystoscope, Cystoscopy with standard of care flexible reusable scope
Guangzhou Red Pine Medical Instrument Co., Ltd., University of Texas Southwestern Medical Center, University of Washington, Penn State University
Bladder Cancer, Bladder Stone, Bladder Outlet Obstruction, Renal Stone, Renal Disease
01/25
07/25
uTRACT, NCT05874921: Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Recruiting
N/A
400
US
Jelmyto (mitomycin) for pyelocalyceal solution, Jelmyto, UGN-101
UroGen Pharma Ltd.
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
04/25
01/28
Maughan, Benjamin
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC

Terminated
2
6
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligometastatic Disease
09/24
09/24
MCC-22-GU-80, NCT05568550: Pembro With Radiation With or Without Olaparib

Recruiting
2
64
US
Pembrolizumab, Keytruda, Olaparib, Lynparza, Androgen Deprivation Therapy, Radiation Therapy
Zin W Myint, Merck Sharp & Dohme LLC
Prostate Cancer
07/26
07/29
LIGHTSPEED-1, NCT06277219: A First-in-Human, Phase 1/2 Study of LAT010 in Patients with Advanced Solid Tumors

Recruiting
1/2
150
US
LAT010, LAT010 + ICI
Latticon Antibody Therapeutics, Inc
Advanced Solid Tumor
12/26
03/27
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
Constantz, Elizabeth
STAGGER, NCT04163432: Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

Recruiting
2
84
US
Durvalumab, Imfinzi, Pemetrexed, Alimta, Carboplatin
University of Utah, AstraZeneca
Non-Small Cell Lung Cancer Metastatic
02/25
02/26
Radojcic, Vedran
AGAVE-201, NCT04710576 / 2020-005107-40: A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Active, not recruiting
2
241
Europe, Canada, US, RoW
Axatilimab, Niktimvo, SNDX-6352
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc
Chronic Graft-versus-host-disease
04/23
09/27
SNDX-6352-0503, NCT03604692: A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD

Completed
1/2
41
US
axatilimab, Niktimvo, SNDX-6352
Syndax Pharmaceuticals
Chronic Graft-versus-host-disease
08/22
10/24
Mendez, Joe
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT04617002: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Available
N/A
US
ONC201 (dordaviprone)
Chimerix
Glioma, H3 K27M
 
 
Diaz, Maria Del Pilar Estevez
NCT04764474: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Recruiting
1
75
Europe, US
HMPL-306
Hutchmed
Isocitrate Dehydrogenase Gene Mutation
09/24
06/25
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24

Download Options